Evidence map›Paper›PMID 41886091›Full record

Trial reportEuropean journal of nutrition2026

Weizmannia coagulans BC99 improved intestinal motility and chronic constipation through regulating gut microbiota: a randomized, double-blind, placebo-controlled trial.

Ying Wu, Yiqing Zhou, Qiuxia Fan, Yinyin Gao, Shuguang Fang, Yukun Sun, Shaobin Gu

Erratum issued Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in European journal of nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT06637397 (Weizmannia Coagulans BC99 Relieves Constipation Symptoms by Regulating Inflammatory, Neurotransmitter, and Lipid Metabolic Pathways), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06637397 nacompletednot on this map

Weizmannia Coagulans BC99 Relieves Constipation Symptoms by Regulating Inflammatory, Neurotransmitter, and Lipid Metabolic Pathways: A Randomized, Double-Blind, Placebo-Controlled Trial

TypeinterventionalSponsorWecare Probiotics Co., Ltd.Ran2024 to 2024Enrolled100ConditionsConstipationArmsProbiotic, Placebo
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Ying WuCollege of Food and Bioengineering, Henan University of Science and Technology, Luoyang, 471023, China.
Yiqing ZhouCollege of Food and Bioengineering, Henan University of Science and Technology, Luoyang, 471023, China.
Qiuxia FanCollege of Food and Bioengineering, Henan University of Science and Technology, Luoyang, 471023, China.
Yinyin GaoCollege of Food and Bioengineering, Henan University of Science and Technology, Luoyang, 471023, China.
Shuguang FangWecare Probiotics R&D Centers (WPC), Wecare Probiotics Co., Ltd, Suzhou, 215200, China.
Yukun SunWecare Probiotics R&D Centers (WPC), Wecare Probiotics Co., Ltd, Suzhou, 215200, China.
Shaobin GuCollege of Food and Bioengineering, Henan University of Science and Technology, Luoyang, 471023, China. shaobingu@haust.edu.cn.

Funding

Key R&D Projects in Henan Province 241111314200Major Science and Technology Special Projects in Henan Province 231100310200Natural Science Foundation of Henan Province 252300423038
6 · The paper itself

Abstract

objectiveThis randomized, double-blind, placebo-controlled study aims to evaluate the effects and underlying mechanisms of an 8-week Weizmannia coagulans BC99 intervention in alleviating constipation in adults.

methodsConstipated adults received BC99 (1 × 1010CFU/day) or a placebo for 8 weeks. Assessment included Completely Spontaneous Bowel Movements (CSBM), Depression Anxiety Stress Scale-21 (DASS-21), and Bristol Fecal Characteristics Scale (BSFS) scores, colonic transit time (CTT), gastrointestinal regulatory factors (ET-1, VIP, GAS, CGRP, SS), gut microbiota composition, and short-chain fatty acids (SCFAs) content in feces. This research was a randomized, double-blind, placebo-controlled study, which received approval from the Ethics Commission of the First Afffliated Hospital of Henan University of Science and Technology at 26 April 2024 (Ethical approval number 2024- 03-K0054), Clinical trial registration number is NCT06637397 ( https://clinicaltrials.gov/ , accessed on 26 April 2024). The present study was conducted from July 2024 to October 2024 at the College of Food and Bioengineering, Henan University of Science and Technology, in accordance with the tenets of the Declaration of Helsinki.

resultsBC99 significantly improved bowel movement frequency, stool characteristics, and psychological well-being. It reduced CTT and modulated levels of gastrointestinal peptides. Gut microbiota analysis revealed increased relative abundance of Lactobacillus, Bifidobacterium and decreased Escherichia-Shigella. BC99 also elevated fecal SCFAs levels (acetic, butyric, isovaleric acid) and inferred the key KEGG pathways associated with fatty acid metabolism and pathogen invasion.

conclusionW. coagulans BC99 effectively alleviates constipation by enhancing intestinal motility, regulating gut microbiota, and increasing SCFA production, demonstrating its potential as a therapeutic probiotic.

Indexed as

ConstipationGastrointestinal MicrobiomeGastrointestinal MotilityProbioticsAdultChronic DiseaseDouble-Blind MethodFatty Acids, VolatileFecesFemaleHumansMaleMiddle AgedFatty Acids, VolatileConstipationGut microbiotaRandomized controlled trialShort-chain fatty acidWeizmannia coagulans BC99

Identifiers

PMID41886091

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.